Matinas BioPharma Holdings MTNB Estimates

NYSE MTNB
$0.18 +0.00 (+0.22%)
As of: Sep 9, 2026 · 3:59 PM EDT
Analyst Estimates

Matinas BioPharma Holdings, Inc. Revenue Estimates

Periods 28
Next Period Q2 23
Consensus 315,906.00

Analysts expect Matinas BioPharma Holdings, Inc. to report revenue of 315,906.00 for Q2 23, against a range of 305,902.52 to 325,909.48. The most recent reported quarter, Q3 24, came in at 0.00.

Metric Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) 1.10 M--0.000.000.000.00------
High Estimate 314,015.58325,909.48333,218.87326,756.920.000.000.000.00-12,958.64-88,929.0931,709.3491,980.1322.44 M
Low Estimate 257,325.42305,902.52302,145.13296,631.080.000.000.000.00-15,097.08-101,354.8127,283.0880,112.2918.51 M
Consensus Estimate 285,670.50315,906.00317,682.00311,694.000.000.000.000.00-14,027.86-95,141.9529,496.2186,046.2120.47 M
Analyst Estimates

Matinas BioPharma Holdings, Inc. Earnings Per Share (EPS) Estimates

Periods 28
Next Period Q4 24
Consensus -0.76

Analysts expect Matinas BioPharma Holdings, Inc. to report earnings per share of -0.76 for Q4 24, against a range of -0.81 to -0.71. The most recent reported quarter, Q3 24, came in at -0.85, a 13.3% beat against the -0.98 consensus.

Metric Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) -1.50-1.50-1.50-1.00-1.50-1.00-0.85--------
High Estimate -1.49-1.37-1.43-1.47-1.50-1.15-0.93-0.71-0.89-0.41-0.140.01-1.48-1.29-1.01
Low Estimate -1.59-1.57-1.57-1.67-1.66-1.25-1.03-0.81-0.97-0.45-0.160.01-1.62-1.51-1.09
Consensus Estimate -1.54-1.47-1.50-1.57-1.58-1.20-0.98-0.76-0.93-0.43-0.150.01-1.55-1.40-1.05